Pipeline
| Target Factor | Indication | Seed | Pre-Clinical | Phase I |
|---|---|---|---|---|
| TUG1 ASO | ||||
| GBM | ||||
| Partner: Nagoya University | ||||
| RUNX1 mRNA | ||||
| Osteo arthritis | ||||
| PrimRNA* Partner: Science Tokyo University |
||||
| ｍRNA | ||||
| Ophthalmic | ||||
| Partner: Senju | ||||
| mRNA | ||||
| Allergy | ||||
| Partner: Kao Corporate | ||||
| mRNA | ||||
| Allergy | ||||
| Partner: Kao Corporate | ||||
| TUG1 ASO successor | ||||
| Solid cancer | ||||
| Partner: Nagoya University | ||||
| PRDM14 siRNA successor | ||||
| Solid cancer | ||||
| Partner: Kanazawa University | ||||
| Genome Edition mRNA | ||||
| Cancer | ||||
| Partner: Undisclosed | ||||
*Subsidiary of NANO MRNA